Growth plate closure is a natural, hormonally driven process that cannot be entirely prevented, but it can be delayed under medical supervision in children and adolescents who face compromised adult height. The primary driver of closure is estrogen, and most interventions that slow the process work by reducing estrogen’s action on the cartilage. Outside of hormonal manipulation, protecting growth plates from physical injury is the other major way to avoid premature closure, since fractures through these areas can trigger early bone bridging and limb-length problems. The science here is more nuanced than a simple how-to, and the distinction between normal closure and pathological early closure matters for understanding what is actually preventable.
Why Growth Plates Close in the First Place
Growth plates are thin layers of cartilage near the ends of long bones, and they are the only place where bones can lengthen. The cartilage cells in these plates go through a sequence: they start in a resting state, then multiply rapidly, then enlarge dramatically, and finally die off as blood vessels invade and hard bone replaces the cartilage.1PubMed. Physiology and pathophysiology of the growth plate This cycle repeats throughout childhood and adolescence, steadily adding length to the skeleton.
Closure happens when the supply of fresh cartilage cells runs out. The resting zone, which acts as a reservoir of progenitor cells, gradually depletes. As those cells are consumed, the plate thins, fewer new cartilage cells are produced, and the remaining cartilage calcifies and is replaced by bone.2PubMed Central. Growth plate closure and therapeutic interventions Once that replacement is complete, the growth plate is gone and no further lengthening is possible. This process is called “senescence” of the growth plate, and it is tightly regulated by hormones, local signaling molecules, and genetics.3PubMed Central. Genetic regulation of the growth plate
Estrogen Is the Master Switch
If there is one hormone responsible for shutting growth plates down, it is estrogen. Both boys and girls produce estrogen, and in both sexes it plays the same role in the growth plate: at low levels during early puberty, estrogen actually stimulates growth, but at the higher levels reached during mid-to-late puberty, it accelerates the consumption of progenitor cells and drives fusion.4PubMed. The role of estrogen receptor α in growth plate cartilage for longitudinal bone growth The clearest proof comes from rare individuals who lack a functioning estrogen receptor or cannot convert testosterone to estrogen. These people keep growing well into adulthood because their growth plates never receive the signal to close.5Dove Medical Press. The role of estrogen in bone growth and formation: changes at puberty
In boys, most of the estrogen that reaches the growth plate is produced locally by an enzyme called aromatase, which converts testosterone into estrogen right inside bone and cartilage tissue. This is why boys’ growth plates close later than girls’: they reach the critical estrogen threshold more slowly. The entire medical strategy for delaying growth plate closure revolves around this biology, either by suppressing puberty to keep estrogen low or by blocking aromatase to prevent estrogen from being made.6PubMed Central. Effects of estrogen on growth plate senescence and epiphyseal fusion
Aromatase Inhibitors and Delayed Fusion
The most studied pharmacological approach to slowing growth plate closure involves aromatase inhibitors, drugs that block the enzyme converting androgens into estrogen. By lowering estrogen levels, these medications slow the maturation of the growth plate’s cartilage cells and keep the plate open longer, buying time for additional growth. The two most commonly studied drugs in pediatric settings are letrozole and anastrozole.
In a randomized trial of pubertal boys with idiopathic short stature, treatment with an aromatase inhibitor alone produced about 18 cm of height gain, growth hormone alone yielded roughly 21 cm, and the combination of both reached about 22.5 cm, all significantly more than the roughly 13 cm expected without treatment. The combination group had the best outcomes, and safety measures including bone density were similar across all groups.7PubMed Central. Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature A network meta-analysis confirmed that all treatment groups, whether using growth hormone, anastrozole, letrozole, or a combination, produced significantly greater height gains than placebo.8PubMed. Comparative effects of growth hormone, testosterone, and aromatase inhibitors on height gain in children and adolescents with idiopathic short statures: a network meta-analysis
In boys with delayed puberty, letrozole combined with testosterone allowed good growth while delaying bone maturation, increasing predicted adult height.9PubMed. Use of aromatase inhibitors to increase final height Real-world data from registry programs also showed that aromatase inhibitor therapy alongside growth hormone in boys was associated with continued height gains over two years, with bone age advancing more slowly than calendar age.10PubMed Central. Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program A recent study of late-pubertal boys with advanced bone age found that combined letrozole and growth hormone therapy increased final adult height by an average of about 6.5 cm beyond what was predicted before treatment.11PubMed Central. Combined Letrozole and Growth Hormone Therapy in Late-Pubertal Males with Advanced Bone Age and Open Knee Physes
Results in girls have been studied as well, though less extensively. The GAIL study looked at early-maturing girls with compromised growth predictions and found that two years of anastrozole plus a puberty-suppressing drug, followed by continued anastrozole alone, yielded a total height gain of about 9.7 cm compared to only 3.6 cm with puberty suppression alone.12PubMed Central. Anastrozole monotherapy further improves near-adult height after the initial combined treatment with leuprorelin and anastrozole in early-maturing girls with compromised growth prediction
Puberty Suppression With GnRH Agonists
A different strategy targets puberty itself. GnRH agonists work by desensitizing the pituitary gland so that it stops signaling the gonads to produce sex hormones. Without rising estrogen or testosterone, bone maturation slows and growth plates stay open longer. These drugs are widely used in children with central precocious puberty, where the body starts puberty far too early and would otherwise close growth plates before the child has had a full period of growth.13PubMed Central. Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly Progressive Puberty
The logic is straightforward: if estrogen drives closure, suppressing the hormonal cascade that produces estrogen will buy the skeleton more time. GnRH agonists and aromatase inhibitors work through different mechanisms but aim at the same target. In practice, some treatment protocols combine both, as the GAIL study demonstrated, using a GnRH agonist to halt puberty while an aromatase inhibitor blocks any residual estrogen production.
Safety Concerns and Trade-Offs
Delaying growth plate closure is not without risks. Estrogen does more than close growth plates; it also helps build and maintain bone density, supports cardiovascular health, and plays roles in brain development during adolescence. Blocking it carries potential downsides.
In boys treated with letrozole for idiopathic short stature, bone density was preserved, but researchers noted more vertebral abnormalities than in a placebo group.14PubMed. Use of aromatase inhibitors in children and adolescents: what’s new? The randomized trial of aromatase inhibitors and growth hormone reported a reassuring safety profile over the treatment period, with no significant differences in bone health, lab values, or adverse events between treatment groups.7PubMed Central. Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature But long-term follow-up data stretching into adulthood remain limited, and the vertebral findings with letrozole have kept clinicians cautious.
There is also a practical concern: aromatase inhibitors raise testosterone levels in boys, since the usual conversion pathway to estrogen is blocked. In the trial data, letrozole produced higher testosterone and lower estrogen than anastrozole did.7PubMed Central. Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature Elevated testosterone can affect mood, acne, and other secondary sexual characteristics, and these side effects need to be weighed against the potential height benefit. These are not over-the-counter supplements; they require pediatric endocrinologist oversight and ongoing monitoring with bone age X-rays.
Protecting Growth Plates From Injury
Outside the hormonal realm, the most common reason growth plates close early is physical damage. A fracture that crosses through a growth plate can disrupt the cartilage cells and trigger bone formation where the plate should remain. This is called premature physeal closure, and it is a real clinical problem in children and adolescents who sustain certain types of fractures.
A retrospective study of pediatric ankle fractures found that about 13% of patients experienced premature physeal closure. The risk was higher in younger children, in more severe fracture types, and when the gap at the growth plate exceeded 2 mm before reduction.15PubMed Central. Premature Physeal Closure Following Pediatric Ankle Physis Fractures: A Retrospective Epidemiological Cohort Study from a Single Swiss Center Nearly half of those who developed premature closure needed surgery to correct a leg-length difference or joint malalignment.
Prevention here means two things: avoiding the injury and managing it properly when it happens. Proper anatomic reduction of growth plate fractures, meaning getting the bones back into alignment as accurately as possible, reduces the risk of bony bridging across the plate. Follow-up imaging is critical because premature closure can develop months after the fracture and may not be immediately obvious.
Overuse injuries are another concern, particularly in young gymnasts. Repetitive compressive loading of the wrist can damage the growth plate at the end of the radius, a condition sometimes called “gymnast’s wrist.” An epidemiological survey of elite female gymnasts found stress-related changes in about 10% of wrists examined, with repetitive compression leading to premature closure of the distal radial growth plate and secondary overgrowth of the neighboring ulna.16PubMed. Gymnast wrist: an epidemiologic survey of ulnar variance and stress changes of the radial physis in elite female gymnasts A study at a gymnastics training center found that physeal injury frequency increased with more years of training and higher weekly training hours.17PubMed Central. Frequency of wrist growth plate injury in young gymnasts at a training center Early recognition matters because continued loading on a stressed growth plate can make the damage permanent. MRI can detect the widening and irregularity of the plate before actual closure occurs, and reducing training load at that stage gives the plate a chance to recover.18PubMed Central. MRI Diagnosis of Gymnast’s Wrist (Distal Radial Physeal Stress Injury)
How Body Weight Influences Growth Plate Timing
A less obvious factor in growth plate closure timing is body weight. Children who are overweight or obese tend to be taller than their peers during childhood, but they also show accelerated skeletal maturation, meaning their bone age runs ahead of their actual age. A cross-sectional study found that overweight children were more than three times as likely to have accelerated bone maturation as children of normal weight, and obese children were nearly five times as likely.19PubMed Central. Accelerated skeletal maturation is associated with overweight and obesity as early as preschool age: a cross-sectional study
The mechanism appears to involve both insulin and a growth factor called IGF-I. Obese children have high insulin levels, and insulin stimulates growth plate activity. Animal research has shown that even brief exposure to a high-fat diet increased bone elongation rates and boosted IGF-I availability in the tissue surrounding growth plates before the animals were technically obese yet.20PubMed Central. Altered IGF-I activity and accelerated bone elongation in growth plates precede excess weight gain in a mouse model of juvenile obesity Leptin, a hormone elevated in obesity, may also play a role in pushing growth plates toward earlier maturation.21PubMed. Putative Effects of Obesity on Linear Growth and Puberty
The practical implication is that while obese children may be tall as eight-year-olds, their growth plates are closing faster, and they may end up shorter as adults than their childhood trajectory suggested. Maintaining a healthy weight during childhood is one modifiable factor that can help keep skeletal maturation on a normal schedule, not because it “prevents” closure but because it avoids accelerating it.
How Doctors Track Growth Plate Status
Any attempt to influence growth plate closure requires knowing where a child stands in the process. The standard tool is a bone age X-ray, typically of the left hand and wrist. A doctor compares the appearance of the bones and their growth plates against a reference atlas to estimate how mature the skeleton is relative to the child’s calendar age. If bone age is significantly ahead of chronological age, it suggests the growth plates are closing faster than expected and the window for intervention is narrowing.
The most widely used reference is the Greulich and Pyle atlas, developed decades ago but still the backbone of bone age assessment. Newer approaches include the Tanner-Whitehouse method, which scores individual bones rather than comparing the whole hand to a reference image. Artificial intelligence systems are increasingly being used alongside human readers to improve consistency. A recent study compared AI bone-age assessments with those from experienced pediatric radiologists and found good agreement, though the research emphasis has been on identifying children whose bone development deviates from normal patterns.22PubMed Central. Developing new methods for the accurate evaluation of children’s bone age based on X-ray images Simplified staging methods have also been developed for adolescents, reducing the complexity of the assessment while maintaining clinical usefulness.23PubMed Central. A Simplified Method for Assessing Bone Age in Adolescents
Bone age X-rays are typically repeated every six to twelve months during treatment so that doctors can assess whether an intervention is working and adjust the plan accordingly. A child on aromatase inhibitors, for example, should show bone age advancing more slowly than calendar age, creating the gap that translates into more time for growth.
Molecular Signaling and Future Approaches
Beyond hormones, growth plate cartilage is regulated by a signaling loop between two molecules called Indian hedgehog and parathyroid hormone-related protein. Indian hedgehog, made by maturing cartilage cells, stimulates the production of PTHrP by cells earlier in the differentiation sequence. PTHrP then keeps those younger cells in a proliferative state, slowing their maturation. Because the less mature cells do not yet produce Indian hedgehog, this creates a feedback loop that controls the pace of the entire growth plate.24PubMed. The parathyroid hormone-related protein and Indian hedgehog feedback loop in the growth plate Disruption of this loop leads to premature or disordered maturation of cartilage cells.25Genes & Diseases. IRE1α regulates the PTHrP-IHH feedback loop to orchestrate chondrocyte hypertrophy and cartilage mineralization
This biology has already led to one approved drug, though not for growth plate preservation specifically. Vosoritide, a stable form of C-natriuretic peptide, was approved in 2021 for children with achondroplasia. It works downstream of the growth plate’s signaling pathways to promote cartilage growth and bone elongation.26ScienceDirect (Osteoarthritis and Cartilage). Expanding horizons of achondroplasia treatment: current options and future developments Whether similar approaches could be adapted to delay closure in children without achondroplasia remains an open question, but the fact that drugs can now modulate growth plate biology at the molecular level represents a significant shift from relying entirely on hormonal manipulation.
Research into biological repair of damaged growth plates is also progressing. When injury causes a bony bridge to form across a growth plate, standard treatment involves surgically removing the bridge and filling the defect with fat or other material to prevent regrowth. But preclinical work has explored using mesenchymal stem cells, growth factors, and scaffolds to regenerate functional cartilage in the damaged area, with the goal of restoring actual growth plate function rather than just preventing further bridging.27PubMed Central. Preclinical studies on mesenchymal stem cell-based therapy for growth plate cartilage injury repair These approaches are still in the animal-model stage, but they point toward a future where “preventing” growth plate closure could mean rebuilding the plate after damage, not just delaying its natural timeline.